Cargando…
Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9
Enteroviruses are one of the most abundant groups of viruses infecting humans, and yet there are no approved antivirals against them. To find effective antiviral compounds against enterovirus B group viruses, an in-house chemical library was screened. The most effective compounds against Coxsackievi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058015/ https://www.ncbi.nlm.nih.gov/pubmed/36986888 http://dx.doi.org/10.3390/pharmaceutics15031028 |
_version_ | 1785016513860730880 |
---|---|
author | Laajala, Mira Kalander, Kerttu Consalvi, Sara Amamuddy, Olivier Sheik Bishop, Özlem Tastan Biava, Mariangela Poce, Giovanna Marjomäki, Varpu |
author_facet | Laajala, Mira Kalander, Kerttu Consalvi, Sara Amamuddy, Olivier Sheik Bishop, Özlem Tastan Biava, Mariangela Poce, Giovanna Marjomäki, Varpu |
author_sort | Laajala, Mira |
collection | PubMed |
description | Enteroviruses are one of the most abundant groups of viruses infecting humans, and yet there are no approved antivirals against them. To find effective antiviral compounds against enterovirus B group viruses, an in-house chemical library was screened. The most effective compounds against Coxsackieviruses B3 (CVB3) and A9 (CVA9) were CL212 and CL213, two N-phenyl benzamides. Both compounds were more effective against CVA9 and CL213 gave a better EC(50) value of 1 µM with high a specificity index of 140. Both drugs were most effective when incubated directly with viruses suggesting that they mainly bound to the virions. A real-time uncoating assay showed that the compounds stabilized the virions and radioactive sucrose gradient as well as TEM confirmed that the viruses stayed intact. A docking assay, taking into account larger areas around the 2-and 3-fold axes of CVA9 and CVB3, suggested that the hydrophobic pocket gives the strongest binding to CVA9 but revealed another binding site around the 3-fold axis which could contribute to the binding of the compounds. Together, our data support a direct antiviral mechanism against the virus capsid and suggest that the compounds bind to the hydrophobic pocket and 3-fold axis area resulting in the stabilization of the virion. |
format | Online Article Text |
id | pubmed-10058015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100580152023-03-30 Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 Laajala, Mira Kalander, Kerttu Consalvi, Sara Amamuddy, Olivier Sheik Bishop, Özlem Tastan Biava, Mariangela Poce, Giovanna Marjomäki, Varpu Pharmaceutics Article Enteroviruses are one of the most abundant groups of viruses infecting humans, and yet there are no approved antivirals against them. To find effective antiviral compounds against enterovirus B group viruses, an in-house chemical library was screened. The most effective compounds against Coxsackieviruses B3 (CVB3) and A9 (CVA9) were CL212 and CL213, two N-phenyl benzamides. Both compounds were more effective against CVA9 and CL213 gave a better EC(50) value of 1 µM with high a specificity index of 140. Both drugs were most effective when incubated directly with viruses suggesting that they mainly bound to the virions. A real-time uncoating assay showed that the compounds stabilized the virions and radioactive sucrose gradient as well as TEM confirmed that the viruses stayed intact. A docking assay, taking into account larger areas around the 2-and 3-fold axes of CVA9 and CVB3, suggested that the hydrophobic pocket gives the strongest binding to CVA9 but revealed another binding site around the 3-fold axis which could contribute to the binding of the compounds. Together, our data support a direct antiviral mechanism against the virus capsid and suggest that the compounds bind to the hydrophobic pocket and 3-fold axis area resulting in the stabilization of the virion. MDPI 2023-03-22 /pmc/articles/PMC10058015/ /pubmed/36986888 http://dx.doi.org/10.3390/pharmaceutics15031028 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Laajala, Mira Kalander, Kerttu Consalvi, Sara Amamuddy, Olivier Sheik Bishop, Özlem Tastan Biava, Mariangela Poce, Giovanna Marjomäki, Varpu Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 |
title | Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 |
title_full | Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 |
title_fullStr | Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 |
title_full_unstemmed | Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 |
title_short | Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 |
title_sort | antiviral mechanisms of n-phenyl benzamides on coxsackie virus a9 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058015/ https://www.ncbi.nlm.nih.gov/pubmed/36986888 http://dx.doi.org/10.3390/pharmaceutics15031028 |
work_keys_str_mv | AT laajalamira antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT kalanderkerttu antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT consalvisara antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT amamuddyoliviersheik antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT bishopozlemtastan antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT biavamariangela antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT pocegiovanna antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 AT marjomakivarpu antiviralmechanismsofnphenylbenzamidesoncoxsackievirusa9 |